Get the Stockscreener App
8.50
0.47%
0.04
After Hours:
8.50
Corbus Pharmaceuticals Holdings Inc stock is traded at $8.50, with a volume of 62,570.
It is up +0.47% in the last 24 hours and up +2.29% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$8.46
Open:
$8.58
24h Volume:
62,570
Relative Volume:
0.40
Market Cap:
$104.01M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-1.8201
EPS:
-4.67
Net Cash Flow:
$-36.86M
1W Performance:
+2.78%
1M Performance:
+2.29%
6M Performance:
-28.69%
1Y Performance:
-83.97%
1-Day Range:
$8.485
$8.8196
1-Week Range:
$8.01
$8.85
52-Week Range:
$4.64
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.50 | 101.20M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Is Corbus Pharmaceuticals Holdings Inc. a good long term investmentOutstanding risk-reward balance - PrintWeekIndia
What drives Corbus Pharmaceuticals Holdings Inc. stock pricePhenomenal capital gains - jammulinksnews.com
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is largely controlled by institutional shareholders who own 51% of the company - Yahoo Finance
(CRBP) Proactive Strategies - news.stocktradersdaily.com
What analysts say about Corbus Pharmaceuticals Holdings Inc. stockTriple returns potential - jammulinksnews.com
why corbus pharmaceuticals holdings inc. stock attracts strong analyst attentionCapital Safe Stock Watchlist - Newser
Why Corbus Pharmaceuticals Holdings Inc. stock attracts strong analyst attentionFree Stock Trading Signals - Newser
What makes Corbus Pharmaceuticals Holdings Inc. stock price move sharplyPotential Rocket List - Newser
How Corbus Pharmaceuticals Holdings Inc. stock performs during market volatilityLow Risk ROI Maximization - Newser
(CRBP) Long Term Investment Analysis - news.stocktradersdaily.com
Bullish Sentiment Across The Cannabis SpaceCheck Full Movers For July 9, 2025 - Benzinga
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Corbus begins multiple ascending dose portion of CRB-913 obesity trial - Investing.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) dropped from Russell Small Cap Completeness Index - MarketScreener
Corbus Pharmaceuticals Reports No Neuropsychiatric Events in Phase 1 SAD Study of CRB-913, Advancing to MAD Portion - Nasdaq
How the (CRBP) price action is used to our Advantage - news.stocktradersdaily.com
Cannabis Stock Movers For June 27, 2025 - Benzinga
Corbus Cancer Drug Shows Promise: New Phase 1 Trial Combines Novel Nectin-4 ADC With Keytruda - Stock Titan
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium - GlobeNewswire
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data? - Seeking Alpha
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $50.88 - Defense World
Bank of America Corp DE Buys 7,207 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
11,027 Shares in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Bought by Two Sigma Advisers LP - Defense World
(CRBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Nuveen Asset Management LLC Has $341,000 Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Dermatomyositis Market Predicted to See Upsurge Through 2034, - openPR.com
Two Sigma Investments LP Purchases 91,205 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Deutsche Bank AG - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Millennium Management LLC - Defense World
Northern Trust Corp Acquires 11,400 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
BNP Paribas Financial Markets Makes New Investment in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Zacks Investment Research
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Corbus Pharmaceuticals CEO Set to Reveal Latest Corporate Strategy at Major Jefferies Healthcare Conference - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $50.88 Average Target Price from Analysts - Defense World
Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating - marketscreener.com
Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating - marketscreener.com
Cannabis Stock Movers For May 20, 2025 - Benzinga
Corbus Pharmaceuticals appoints new board chair - Investing.com Australia
Corbus Pharmaceuticals appoints new board chair By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Appoints New Chair of the Board - TipRanks
Corbus Pharmaceuticals (CRBP) Names New Chair to Board of Direct - GuruFocus
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):